Martin Glennie

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Martin J. Glennie is professor of immunochemistry (antibodies) at the University of Southampton, United Kingdom.[1]

Career[edit]

Glennis earned his BSc and PhD at the University of Southampton, and is the current Head of the Cancer Sciences Unit there.[1] Glennie is on the editorial board of the scientific journal mAbs (monoclonal antibodies) published by the Taylor & Francis Group.[2]

Public media interest[edit]

The clinical trial of an anti-CD40 monoclonal antibody chiLOB7/4 developed in Glennie's laboratory was reported by The Daily Telegraph in August 2013.[3] Glennie stressed that “Ipilimumab works by taking the brakes off part of the immune system called T cells, while our compound revs up the T cells – it is like giving them a caffeine hit.".[3]

Personal life[edit]

Glennie is a keen angler, winning second prize (Lupa cup) in the Baltimore Deep Sea angling Festival 2014, South West Ireland.[4]

References[edit]

  1. ^ a b "University of Southampton Faculty of Medicine Staff page". University of Southampton. Retrieved 11 December 2014.
  2. ^ "mAbs editorial board". Retrieved 11 December 2014.
  3. ^ a b "New Immunity Boosting Drug Helps Body Kill Cancer". Retrieved 11 December 2014.
  4. ^ "Baltimore Deep Sea Angling Festival 2014". Retrieved 11 December 2014.